MajorDirect oral anticoagulants (factor Xa inhibitors)×Non-steroidal anti-inflammatory drugs (NSAIDs)
Updated · Methodology
Mechanism
Edoxaban blocks clotting factor Xa (edoxaban SmPC, EMA). Ibuprofen, like other non-steroidal anti-inflammatory drugs (NSAIDs), can reduce platelet aggregation, prolong bleeding time and cause ulcers and bleeding in the stomach and gut (ibuprofen summary of product characteristics, SmPC). Bleeding time can stay prolonged for up to a day after ibuprofen is stopped (ibuprofen SmPC). In clinical studies, NSAIDs given with edoxaban increased clinically relevant bleeding (edoxaban SmPC, European Medicines Agency, EMA). Among NSAIDs, pharmacokinetic data with edoxaban exist only for naproxen, which did not change edoxaban levels (edoxaban SmPC, EMA).
Symptoms
The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Ibuprofen adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (ibuprofen SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).
Management
The edoxaban summary of product characteristics (SmPC) does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, EMA). Give ibuprofen at the lowest effective dose for the shortest time. Use NSAIDs with caution together with drugs that raise the risk of gastrointestinal bleeding (ibuprofen SmPC). If long-term NSAID treatment cannot be avoided, monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, FDA). During long-term ibuprofen treatment, check kidney and liver function, haematological parameters and blood counts (ibuprofen SmPC). In older patients and in those with a previous ulcer, start ibuprofen at the lowest dose and give it with gastroprotection (misoprostol or a proton pump inhibitor). Consider the same protection when other drugs raise the risk of gastrointestinal bleeding (ibuprofen SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). In kidney disease, keep the ibuprofen dose as low as possible and check kidney function regularly (ibuprofen SmPC). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Stop ibuprofen at once if gastrointestinal bleeding or an ulcer occurs (ibuprofen SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ibuprofeno (nº registro 63597), secciones 4.2, 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 63597, revisión 04/2025, secciones 4.2, 4.4 y 4.5
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2